Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia. | Leukemia | 2025 | 40533497 | PubTator, text mining | PubMed |
| Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study. | Blood Adv | 2025 | 40505061 | PubTator, text mining | PubMed |
| Insights into the pathogenesis and biology of chronic lymphocytic leukemia through analysis of its B-cell receptor. | Leuk Lymphoma | 2025 | 40493712 | PubTator, text mining | PubMed |
| Transdifferentiation of Multiple Myeloma into Histiocytic Sarcoma: Case Report of a Highly Unusual Phenomenon. | Pathobiology | 2025 | 40484006 | PubTator, text mining | PubMed |
| Antigen selection reflected in the subclonal architecture of the B-cell receptor immunoglobulin gene repertoire in splenic marginal zone lymphoma. | Hemasphere | 2025 | 40433552 | PubTator, text mining | PubMed |
| Association of [18F]-FDG PET/CT-Derived Radiomic Features with Clinical Outcomes and Genomic Profiles in Patients with Chronic Lymphocytic Leukemia. | Diagnostics (Basel) | 2025 | 40428274 | PubTator, text mining | PubMed |
| CD38 prognostic role in chronic lymphocytic leukemia patients treated with standard chemotherapy or targeted agents: a monocentric real-life experience. | Front Oncol | 2025 | 40406271 | PubTator, text mining | PubMed |
| A Case of Multiple Myeloma in a Patient in Treatment for Chronic Lymphocytic Leukemia. | Mediterr J Hematol Infect Dis | 2025 | 40375915 | PubTator, text mining | PubMed |
| Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL. | Blood Adv | 2025 | 40353821 | PubTator, text mining | PubMed |
| Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia - real-world data from a hemato-oncology center. | Neoplasma | 2025 | 40353625 | PubTator, text mining | PubMed |
| Diagnosis and treatment of chronic lymphocytic leukemia: 2025 recommendations of the Brazilian Group of Chronic Lymphocytic Leukemia of the Brazilian Association of Hematology and Hemotherapy (ABHH). | Hematol Transfus Cell Ther | 2025 | 40347842 | PubTator, text mining | PubMed |
| Naive and Memory B Cell BCR Repertoires in Individuals Immunized with an Inactivated SARS-CoV-2 Vaccine. | Vaccines (Basel) | 2025 | 40333337 | PubTator, text mining | PubMed |
| Analysis of Stereotyped B-Cell Receptor Frequencies Among Portuguese De Novo-Diagnosed Chronic Lymphocytic Leukemia Patients (PAIS Study). | Cancers (Basel) | 2025 | 40282492 | PubTator, text mining | PubMed |
| ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker. | Leukemia | 2025 | 40275070 | PubTator, text mining | PubMed |
| Simultaneous polyclonal antibody sequencing and epitope mapping by cryo electron microscopy and mass spectrometry. | Elife | 2025 | 40266252 | PubTator, text mining | PubMed |
| HPV16 neutralizing monoclonal antibodies show evidence for common developmental pathways and public epitopes. | bioRxiv | 2025 | 40236113 | PubTator, text mining | PubMed |
| Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. | Blood | 2025 | 40198878 | PubTator, text mining | PubMed |
| Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia. | Blood Adv | 2025 | 40179394 | PubTator, text mining | PubMed |
| Characterisation of Cytotoxicity-Related Receptors on γδ T Cells in Chronic Lymphocytic Leukaemia. | Cells | 2025 | 40136700 | PubTator, text mining | PubMed |
| Efficient De Novo Assembly of 100 kb-Scale Human Functional Immunoglobulin Heavy Variable (IGHV) Gene Fragments In Vitro. | ACS Synth Biol | 2025 | 40135783 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=7